Indian Pharmacopoeia Commission (IPC) Joins Pharmacopoeial Discussion Group for Global Expansion

Recently the Pharmacopoeial Discussion Group (PDG), which comprises the European Pharmacopoeia (Ph. Eur.), the Japanese Pharmacopoeia (JP), and the United States Pharmacopeia (USP), with the World Health Organization (WHO) as an observer welcomed the Indian Pharmacopoeia Commission (IPC) as a participant in the PDG pilot for global expansion.

During the PDG Annual Meeting in 2021, the PDG decided to launch a pilot for the expansion of membership by inviting the global pharmacopoeias that were interested in participating in this pilot to submit their applications, which were then evaluated based on objective entry criteria.

After reviewing each application, the PDG agreed to start the pilot phase with the IPC, the only applicant that met all the PDG requirements in the entry criteria for the pilot.

A one-year expansion pilot will allow established PDG members to refine their working methods further and, at the end of the pilot, will identify any changes necessary to ensure that PDG remains efficient before a broader rollout is implemented.

The pilot one-year for expansion is will be starting soon and the PDG Annual Meeting to be held virtually in October 2022 and aims to provide strong, science-based harmonized pharmacopeial standards.

Click this LINK to read the press release and PDG thank the other applicants for their interest in the pilot.